BioRestorative Therapies Profit Margin

BioRestorative Therapies (BRTX) currently reports a profit margin of -3089.55% as of March 2026. That compares with -3093.59% in the prior-year period — up 0.1% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore BioRestorative Therapies's profit margin history and peer comparisons.

BioRestorative Therapies's profit margin increased from -3093.59% to -3089.55% — a 0.1% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioRestorative Therapies's profit margin of -3089.55% is lower than the Healthcare sector average of 15.29%. That is roughly 20302.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but BioRestorative Therapies's current -3089.55% should be judged against Healthcare norms (sector average: 15.29%) and against BRTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3089.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for BioRestorative Therapies, and consider following BRTX for alerts when major investors trade the stock.